Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients

T. Gislason, J. Hedner, L. Terenius, G. Bisette, Charles Nemeroff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The cerebrospinal fluid (CSF) concentrations of thyrotropin-releasing hormone (TRH), substance P (SP), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were measured in 15 consecutive patients with the sleep apnea syndrome (SAS) and in healthy control subjects. Second measurements were performed 6 months after surgical treatment in 10 of the patients. The mean (± SD) concentration of TRH-like immunoreactive material (TRH-LIM) (pg/ml) did not differ significantly between patients with SAS (8.1 ± 2.8) and control subjects (7.5 ± 2.2). However, postoperatively, this concentration was increased in the six clinically cured patients with SAS, from 6.9 ± 2.7 to 9.4 ± 1.6 (p < 0.03). Substance P-like immunoreactive material (SP-LIM) was higher in untreated patients with SAS than in control subjects: 19.2 ± 6.7 versus 14.4 ± 4.2 fmol/ml (p < 0.02), and the level remained high after operation in the group treated surgically. The HVA, 5-HIAA, and MHPG concentrations were similar in patients with SAS and control subjects, and no consistent changes were found postoperatively. The CSF deviations in TRH-LIM and SP-LIM concentrations in the patients may reflect a primary central nervous system defect or they may be secondary to intermittent nocturnal hypoxia, progressive hypercapnia, and/or sleep fragmentation. In this sense, both these systems may be markers of SAS-SP as a 'trait' marker and TRH as an indicator of the current state.

Original languageEnglish
Pages (from-to)784-786
Number of pages3
JournalAmerican Review of Respiratory Disease
Volume146
Issue number3
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Thyrotropin-Releasing Hormone
Sleep Apnea Syndromes
Substance P
Cerebrospinal Fluid
Homovanillic Acid
Hydroxyindoleacetic Acid
Glycols
Sleep Deprivation
Hypercapnia
Healthy Volunteers
Central Nervous System

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients. / Gislason, T.; Hedner, J.; Terenius, L.; Bisette, G.; Nemeroff, Charles.

In: American Review of Respiratory Disease, Vol. 146, No. 3, 01.01.1992, p. 784-786.

Research output: Contribution to journalArticle

@article{5317376e67fe4d319627aad89147cc1b,
title = "Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients",
abstract = "The cerebrospinal fluid (CSF) concentrations of thyrotropin-releasing hormone (TRH), substance P (SP), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were measured in 15 consecutive patients with the sleep apnea syndrome (SAS) and in healthy control subjects. Second measurements were performed 6 months after surgical treatment in 10 of the patients. The mean (± SD) concentration of TRH-like immunoreactive material (TRH-LIM) (pg/ml) did not differ significantly between patients with SAS (8.1 ± 2.8) and control subjects (7.5 ± 2.2). However, postoperatively, this concentration was increased in the six clinically cured patients with SAS, from 6.9 ± 2.7 to 9.4 ± 1.6 (p < 0.03). Substance P-like immunoreactive material (SP-LIM) was higher in untreated patients with SAS than in control subjects: 19.2 ± 6.7 versus 14.4 ± 4.2 fmol/ml (p < 0.02), and the level remained high after operation in the group treated surgically. The HVA, 5-HIAA, and MHPG concentrations were similar in patients with SAS and control subjects, and no consistent changes were found postoperatively. The CSF deviations in TRH-LIM and SP-LIM concentrations in the patients may reflect a primary central nervous system defect or they may be secondary to intermittent nocturnal hypoxia, progressive hypercapnia, and/or sleep fragmentation. In this sense, both these systems may be markers of SAS-SP as a 'trait' marker and TRH as an indicator of the current state.",
author = "T. Gislason and J. Hedner and L. Terenius and G. Bisette and Charles Nemeroff",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "146",
pages = "784--786",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients

AU - Gislason, T.

AU - Hedner, J.

AU - Terenius, L.

AU - Bisette, G.

AU - Nemeroff, Charles

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The cerebrospinal fluid (CSF) concentrations of thyrotropin-releasing hormone (TRH), substance P (SP), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were measured in 15 consecutive patients with the sleep apnea syndrome (SAS) and in healthy control subjects. Second measurements were performed 6 months after surgical treatment in 10 of the patients. The mean (± SD) concentration of TRH-like immunoreactive material (TRH-LIM) (pg/ml) did not differ significantly between patients with SAS (8.1 ± 2.8) and control subjects (7.5 ± 2.2). However, postoperatively, this concentration was increased in the six clinically cured patients with SAS, from 6.9 ± 2.7 to 9.4 ± 1.6 (p < 0.03). Substance P-like immunoreactive material (SP-LIM) was higher in untreated patients with SAS than in control subjects: 19.2 ± 6.7 versus 14.4 ± 4.2 fmol/ml (p < 0.02), and the level remained high after operation in the group treated surgically. The HVA, 5-HIAA, and MHPG concentrations were similar in patients with SAS and control subjects, and no consistent changes were found postoperatively. The CSF deviations in TRH-LIM and SP-LIM concentrations in the patients may reflect a primary central nervous system defect or they may be secondary to intermittent nocturnal hypoxia, progressive hypercapnia, and/or sleep fragmentation. In this sense, both these systems may be markers of SAS-SP as a 'trait' marker and TRH as an indicator of the current state.

AB - The cerebrospinal fluid (CSF) concentrations of thyrotropin-releasing hormone (TRH), substance P (SP), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were measured in 15 consecutive patients with the sleep apnea syndrome (SAS) and in healthy control subjects. Second measurements were performed 6 months after surgical treatment in 10 of the patients. The mean (± SD) concentration of TRH-like immunoreactive material (TRH-LIM) (pg/ml) did not differ significantly between patients with SAS (8.1 ± 2.8) and control subjects (7.5 ± 2.2). However, postoperatively, this concentration was increased in the six clinically cured patients with SAS, from 6.9 ± 2.7 to 9.4 ± 1.6 (p < 0.03). Substance P-like immunoreactive material (SP-LIM) was higher in untreated patients with SAS than in control subjects: 19.2 ± 6.7 versus 14.4 ± 4.2 fmol/ml (p < 0.02), and the level remained high after operation in the group treated surgically. The HVA, 5-HIAA, and MHPG concentrations were similar in patients with SAS and control subjects, and no consistent changes were found postoperatively. The CSF deviations in TRH-LIM and SP-LIM concentrations in the patients may reflect a primary central nervous system defect or they may be secondary to intermittent nocturnal hypoxia, progressive hypercapnia, and/or sleep fragmentation. In this sense, both these systems may be markers of SAS-SP as a 'trait' marker and TRH as an indicator of the current state.

UR - http://www.scopus.com/inward/record.url?scp=0026793866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026793866&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 784

EP - 786

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -